SG Americas Securities
VTGN icon

SG Americas Securities’s VistaGen Therapeutics VTGN Stock Holding History

SG Americas Securities’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,720
Closed -$10K – 3231
2023
Q1 		$10K Buy
2,720
+2,012
+284% +$10.6K ﹤0.01% 3187
2022
Q4 		$2K Sell
708
-3,256
-82% -$12.3K ﹤0.01% 3018
2022
Q3 		$18K Buy
3,964
+2,983
+304% +$29.6K ﹤0.01% 3107
2022
Q2 		$26K Sell
981
-2,991
-75% -$106K ﹤0.01% 3327
2022
Q1 		$148K Buy
3,972
+2,623
+194% +$114K ﹤0.01% 2589
2021
Q4 		$79K Sell
1,349
-1,182
-47% -$76.9K ﹤0.01% 3126
2021
Q3 		$208K Buy
+2,531
New +$220K ﹤0.01% 3212
2021
Q1 		– Sell
-490
Closed -$29K – 3586
2020
Q4 		$29K Buy
+490
New +$12.5K ﹤0.01% 3185

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SG Americas Securities's VTGN Position: Q2 2023 in Review

SG Americas Securities sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 2,720 shares — an estimated $10K sold.

SG Americas Securities first reported a position in VTGN in Q4 2020 and held it in 8 quarters. The position peaked at $208K in Q3 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • SG Americas Securities reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • SG Americas Securities sold 2,720 VistaGen Therapeutics shares in Q2 2023, an estimated $10K.
  • SG Americas Securities first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 8 quarters.
  • SG Americas Securities's VistaGen Therapeutics position peaked at $208K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on SG Americas Securities's 13F filing for Q2 2023, filed 10 Jul 2023.